Sarepta Therapeutics | Sustainability Performance
Engages in the development of genetic medicine therapies, focusing on rare diseases and neuromuscular conditions.
1980
United States
1,001 - 5,000 employees
Biotechnology
$1B - 10B in revenue
Not profitable
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#4530
Overallⓘ#820
in United Statesⓘ#91
in BiotechnologyⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Controversy level
- Sarepta's gene therapy for Duchenne muscular dystrophy received accelerated FDA approval amid controversy over clinical evidence.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
7-10
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.